MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 471035 | Name: Quazinone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Quazinone, is a phosphodiesterase 3 (PDE3) inhibitor and novel cardiotonic agent with vasodilating properties.

Chemical Structure

Quazinone
Quazinone
CAS#70018-51-8

Theoretical Analysis

MedKoo Cat#: 471035

Name: Quazinone

CAS#: 70018-51-8

Chemical Formula: C11H10ClN3O

Exact Mass: 235.0512

Molecular Weight: 235.67

Elemental Analysis: C, 56.06; H, 4.28; Cl, 15.04; N, 17.83; O, 6.79

Price and Availability

Size Price Availability Quantity
10mg USD 250.00
25mg USD 480.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Quazinone; Ro 13-6438
IUPAC/Chemical Name
(3R)-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one
InChi Key
BHZFZYLBVSWUMT-ZCFIWIBFSA-N
InChi Code
InChI=1S/C11H10ClN3O/c1-6-10(16)14-11-13-9-4-2-3-8(12)7(9)5-15(6)11/h2-4,6H,5H2,1H3,(H,13,14,16)/t6-/m1/s1
SMILES Code
O=C1NC2=NC3=C(C(Cl)=CC=C3)CN2[C@@H]1C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO and Ethanol
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO and Ethanol
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Quazinone is a selective inhibitor of phosphodiesterase 3 (PDE3) with positive inotropic and vasodilating properties. It induces relaxation of precontracted isolated human cavernous smooth muscle. Quazinone increases myocardial contractile force in anesthetized open-chest dogs in a dose-dependent manner, as well as decreases systolic and diastolic blood pressure. It also inhibits DNA synthesis induced by the PDGF isoform PDGF-BB in bovine coronary artery smooth muscle cells in a concentration-dependent manner.
In vitro activity:
Quazinone had potency at least equal to that of papaverine (a non-selective PDE inhibitor) and had a superior effect compared to Rolipram (a selective PDE IV inhibitor) and zaprinast (a selective PDE V inhibitor). The relaxation effect of PDE inhibitors was evaluated in an organ-bath study. This study provides the rationale and opens the possibility of using selective PDE inhibitors in the treatment of patients with erectile dysfunction. Reference: World J Urol. 1997;15(1):32-5. https://pubmed.ncbi.nlm.nih.gov/9066092/
In vivo activity:
Quazinone increased tension development of isolated guinea pig left atria in a concentration-dependent manner with an EC50 of 30 microM, but had no stimulant effect on the spontaneous rate of right atria. In chronically instrumented, conscious dogs Quazinone increased myocardial contractility after administration of 0.03-0.3 mg/kg i.v. or 3-10 mg/kg p.o. The effects persisted for greater than 8 h after oral administration of 10 mg/kg. The inotropic effects were accompanied by a modest increase in heart rate. Reference: J Cardiovasc Pharmacol. 1984 May-Jun;6(3):511-9. https://pubmed.ncbi.nlm.nih.gov/6202980/
Solvent mg/mL mM
Solubility
DMSO 5.0 21.22
Ethanol 1.0 4.24
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 235.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Fryknäs M. Targeting tumor cells based on Phosphodiesterase 3A expression. Exp Cell Res. 2017 Dec 15;361(2):308-315. doi: 10.1016/j.yexcr.2017.10.032. Epub 2017 Oct 26. PMID: 29107068. 2. Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol. 1997;15(1):32-5. doi: 10.1007/BF01275154. PMID: 9066092. 3. Braun S, Shargorodsky B, Talit U, Laniado S. Haemodynamic effects of Ro 13-6438, a new inotropic agent with vasodilating properties. Drugs Exp Clin Res. 1986;12(5):381-4. PMID: 3720522. 4. Eigenmann R, Gerold M, Holck M. Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):511-9. doi: 10.1097/00005344-198405000-00021. PMID: 6202980.
In vitro protocol:
1. Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Fryknäs M. Targeting tumor cells based on Phosphodiesterase 3A expression. Exp Cell Res. 2017 Dec 15;361(2):308-315. doi: 10.1016/j.yexcr.2017.10.032. Epub 2017 Oct 26. PMID: 29107068. 2. Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol. 1997;15(1):32-5. doi: 10.1007/BF01275154. PMID: 9066092.
In vivo protocol:
1. Braun S, Shargorodsky B, Talit U, Laniado S. Haemodynamic effects of Ro 13-6438, a new inotropic agent with vasodilating properties. Drugs Exp Clin Res. 1986;12(5):381-4. PMID: 3720522. 2. Eigenmann R, Gerold M, Holck M. Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):511-9. doi: 10.1097/00005344-198405000-00021. PMID: 6202980.
1: Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Fryknäs M. Targeting tumor cells based on Phosphodiesterase 3A expression. Exp Cell Res. 2017 Dec 15;361(2):308-315. doi: 10.1016/j.yexcr.2017.10.032. Epub 2017 Oct 26. PMID: 29107068. 2: Sitdikova GF, Islamov RR, Mukhamedyarov MA, Permyakova VV, Zefirov AL, Palotás A. Modulation of neurotransmitter release by carbon monoxide at the frog neuro-muscular junction. Curr Drug Metab. 2007 Feb;8(2):177-84. doi: 10.2174/138920007779815940. PMID: 17305496. 3: Fryknäs M, Rickardson L, Wickström M, Dhar S, Lövborg H, Gullbo J, Nygren P, Gustafsson MG, Isaksson A, Larsson R. Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model. J Biomol Screen. 2006 Aug;11(5):457-68. doi: 10.1177/1087057106288048. PMID: 16928983. 4: Rickards KJ, Page CP, Cunningham FM. Allergen challenge alters lymphocyte phosphodiesterase activity in horses with heaves. Pulm Pharmacol Ther. 2004;17(3):163-72. doi: 10.1016/j.pupt.2004.02.001. PMID: 15123226. 5: Rickards KJ, Andrews MJ, Waterworth TH, Alexander GB, Cunningham FM. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther. 2003 Aug;26(4):277-82. doi: 10.1046/j.1365-2885.2003.00486.x. PMID: 12887610. 6: Fung E, Fiscus RR. Adrenomedullin induces direct (endothelium-independent) vasorelaxations and cyclic adenosine monophosphate elevations that are synergistically enhanced by brain natriuretic peptide in isolated rings of rat thoracic aorta. J Cardiovasc Pharmacol. 2003 Jun;41(6):849-55. doi: 10.1097/00005344-200306000-00004. PMID: 12775961. 7: Musialek P, Rigg L, Terrar DA, Paterson DJ, Casadei B. Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors. J Mol Cell Cardiol. 2000 Oct;32(10):1831-40. doi: 10.1006/jmcc.2000.1216. PMID: 11013127. 8: Osinski MT, Schrör K. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis. Biochem Pharmacol. 2000 Aug 1;60(3):381-7. doi: 10.1016/s0006-2952(00)00328-2. PMID: 10856433. 9: Kühn R, Uckert S, Stief CG, Truss MC, Lietz B, Bischoff E, Schramm M, Jonas U. Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways. Urol Res. 2000 Apr;28(2):110-5. doi: 10.1007/s002400050147. PMID: 10850633. 10: Wang X, Wang W, Li Y, Bai Y, Fiscus RR. Mechanism of SNAP potentiating antiproliferative effect of calcitonin gene-related peptide in cultured vascular smooth muscle cells. J Mol Cell Cardiol. 1999 Sep;31(9):1599-606. doi: 10.1006/jmcc.1999.0991. PMID: 10471344. 11: Tsuji F, Oki K, Senda T, Horiuchi M, Mita S. Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells. Immunol Lett. 1999 Jun 1;68(2-3):275-9. doi: 10.1016/s0165-2478(99)00051-6. PMID: 10424432. 12: Denis D, Riendeau D. Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes. Eur J Pharmacol. 1999 Feb 19;367(2-3):343-50. doi: 10.1016/s0014-2999(98)00987-x. PMID: 10079010. 13: Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol. 1997;15(1):32-5. doi: 10.1007/BF01275154. PMID: 9066092. 14: Stief CG, Taher A, Truss M, Becker AJ, Schulz-Knappe P, Meyer M, Uckert S, Forssmann WG, Jonas U. Phosphodiesterase isoenzymes in human ureteral smooth muscle: identification, characterization, and functional effects of various phosphodiesterase inhibitors in vitro. Urol Int. 1995;55(4):183-9. doi: 10.1159/000282783. PMID: 8588263. 15: Taher A, Schulz-Knappe P, Meyer M, Truss M, Forssmann WG, Stief CG, Jonas U. Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro. World J Urol. 1994;12(5):286-91. doi: 10.1007/BF00191209. PMID: 7866426. 16: Simonton CA, Daly PA, Kereiakes D, Modin G, Chatterjee K. Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents. Chest. 1987 Jul;92(1):118-23. doi: 10.1378/chest.92.1.118. PMID: 2954776. 17: Komajda M, Lechat P, Elkik F, Grosgogeat Y. RO 13-6438 in congestive heart failure: dose-response relationship after 3 single doses. Fundam Clin Pharmacol. 1987;1(6):459-70. doi: 10.1111/j.1472-8206.1987.tb00579.x. PMID: 3447933. 18: McKay RG, Miller MJ, Ferguson JJ, Momomura S, Sahagian P, Grossman W, Pasternak RC. Assessment of left ventricular end-systolic pressure-volume relations with an impedance catheter and transient inferior vena cava occlusion: use of this system in the evaluation of the cardiotonic effects of dobutamine, milrinone, Posicor and epinephrine. J Am Coll Cardiol. 1986 Nov;8(5):1152-60. doi: 10.1016/s0735-1097(86)80395-3. PMID: 3760389. 19: Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med. 1986 Feb 6;314(6):349-58. doi: 10.1056/NEJM198602063140605. PMID: 2418353. 20: Braun S, Shargorodsky B, Talit U, Laniado S. Haemodynamic effects of Ro 13-6438, a new inotropic agent with vasodilating properties. Drugs Exp Clin Res. 1986;12(5):381-4. PMID: 3720522.

View History

L 696418

L 696418